One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Nabriva Therapeutics plc logo
Nabriva Therapeutics plc NBRV
report update icon

Quarterly report 2023-Q2
added 11-21-2026

Nabriva Therapeutics plc Income Statement 2022-2011 | NBRV

Brief overview of financial results at Nabriva Therapeutics plc

The conclusions below are based on five years of reported results. Revenue reported by Nabriva Therapeutics plc was 5.3 million dollars at the beginning of the period and 36.9 million dollars at the end. The cumulative result was +594.4%, corresponding to roughly 47.3% per year. Revenue growth reflects a pronounced phase of business expansion.

EBITDA changed from −$73.3 million to −$55.3 million (+24.6%). EBITDA lagged revenue, showing weaker operating momentum. Comparing the endpoints gives EBITDA margins of −1378.8% and −149.6%. The increased EBITDA share is a positive sign.

The final result was −74.4 million dollars initially and −57.2 million dollars in the final year. The direction improved, yet positive earnings are still absent.

The market value of the business moved from $1.5 billion to $4.1 million, or −99.7%. The market has not yet confirmed the improvement in fundamentals.

What the figures show

Positive developments coexist with areas of weakness. Key strengths include a larger revenue base, higher operating efficiency and a stronger final result. The weaker side of the profile includes lower investor confidence and a narrow EBITDA buffer. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.

Annual Income Statement Nabriva Therapeutics plc

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

4.1 M 787 K 1.23 M 100 M 101 M 1.53 B 232 M 95.4 M - - - -

Shares

2.68 M 1.73 M 514 K 7.42 M 5.08 M 29.8 M 2.15 M 1.06 M 325 K - - -

Historical Prices

1.53 0.454 2.39 13.5 19.8 51.4 108 90.1 - - - -

Net Income

-57.2 M -49.4 M -69.5 M -82.8 M -115 M -74.4 M -54.9 M -47 M -14.2 M 15.5 M - -

Revenue

36.9 M 28.9 M 5.03 M 9.48 M 9.66 M 5.32 M 6.48 M - - - - -

Cost of Revenue

28.6 M 13.1 M 766 K 70 K - - - - - - - -

Gross Profit

8.35 M 15.7 M 4.26 M 7.68 M - - - - - - - -

Operating Income

-55.5 M -48.5 M -66.1 M -79.5 M -114 M -73.8 M -55 M -27.8 M -10.7 M - - -

Interest Expense

698 K 901 K 1.65 M 3.39 M 133 K 43 K 75 K 22.1 M 2.91 M - - -

EBITDA

-55.3 M -48.2 M -65.7 M -79.1 M -114 M -73.3 M -54.8 M -27.6 M -10.5 M 28.1 M - -

Operating Expenses

63.8 M 64.3 M 70.4 M 87.2 M 31.7 M 23.4 M 61.5 M 31.5 M 13.1 M - - -

General and Administrative Expenses

45.3 M 51.6 M 55.3 M 62.5 M 41.7 M 29.5 M 13.5 M 7.92 M 3.74 M 3.91 M - -

All numbers in USD currency

Quarterly Income Statement Nabriva Therapeutics plc

2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

3.23 M 3.2 M 143 K 2.73 M 2.53 M 2.35 M 164 K 2.02 M 40.6 M 26.4 M -105 M 145 M 113 M 9.46 M -64.7 M 75.2 M 72.5 M 68.7 M -40.3 M 58.4 M 40.5 M 36.9 M 2.31 M 28.1 M 27.2 M 27.2 M 2.72 M 21.3 M 21.3 M 2.12 M - - - - - - - - - - - - - - - - - - - -

Net Income

-12.1 M -8.7 M -22.8 M -11.5 M -11.1 M -11.8 M -13.1 M -10.7 M -11.8 M -14 M -17.8 M -13 M -15.4 M -23.3 M -23 M -17.8 M -21.7 M -20.2 M -30.8 M -52.8 M -17.8 M -13.3 M -22.3 M -22.3 M -14.6 M -15.2 M -15.2 M -14 M -12.1 M -13.6 M -7.96 M -8.42 M -24.5 M -6.06 M - - - - - - - - - - - - - - - -

Revenue

2.24 M 7.59 M 10.6 M 9.15 M 9.19 M 8.02 M 9.26 M 8.86 M 8.24 M 2.53 M 2.46 M 1.29 M 487 K 789 K 333 K 6.92 M 525 K 1.7 M 797 K 461 K 847 K 7.55 M 1.12 M 1.47 M 1.05 M 1.68 M - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

9.07 M 4.44 M 16.3 M 4.42 M 4.46 M 3.36 M 5.27 M 4.2 M 3.62 M 62 K 365 K 25 K 368 K 8 K 55 K 15 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

-6.83 M 3.15 M -5.78 M 4.74 M 4.74 M 4.66 M 4 M 4.66 M 4.62 M 2.47 M 2.1 M 1.27 M 119 K 781 K 278 K 6.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-12 M -8.48 M -22.3 M -11.2 M -10.4 M -11.6 M -12.9 M -10.8 M -11.4 M -13.4 M -18.3 M -13.2 M -14.5 M -20.2 M -22.1 M -17.2 M -21 M -19.2 M -30.9 M -52.9 M -17.7 M -12.9 M -22.3 M -20.7 M -15.6 M -15.2 M -14.7 M -14.1 M -11.5 M -14.7 M -10.2 M -8.33 M -5.52 M -3.67 M - - - - - - - - - - - - - - - -

Interest Expense

1 K -194 K 1.13 M -146 K -198 K -215 K 1.15 M -221 K -236 K -221 K 573 K 450 K -634 K 798 K 99 K -10 K 56 K 70 K -100 K -54 K -141 K 23 K 101 K 301 K 3 K 22 K - 35 K - 18 K - - - - - - - - - - - - - - - - - - - -

EBITDA

-12 M -8.45 M -22.3 M -11.2 M -10.3 M -11.5 M -12.8 M -10.7 M -11.3 M -13.3 M -18.2 M -13.1 M -14.3 M -20.1 M -21.8 M -17.3 M -20.9 M -19.1 M -30.8 M -52.8 M -17.6 M -12.7 M -22.1 M -20.6 M -15.5 M -15.1 M -14.7 M -13.9 M -11.4 M -14.7 M -10.2 M -8.33 M -5.52 M -3.67 M - - - - - - - - - - - - - - - -

Operating Expenses

5.19 M 11.6 M 16.6 M 15.9 M 15.1 M 16.2 M 16.9 M 15.5 M 16 M 15.9 M 20.4 M 14.5 M 14.6 M 21 M 22.3 M 24.1 M 21.5 M 20.9 M 31.7 M 53.4 M 18.6 M 20.4 M 23.4 M 22.2 M 16.6 M 16.9 M 17 M 15 M 13.3 M 16.1 M 11.2 M 9.62 M 6.42 M 4.27 M - - - - - - - - - - - - - - - -

General and Administrative Expenses

4.11 M 9 M 9.61 M 11.9 M 11 M 12.7 M 14.5 M 12.3 M 12.9 M 12 M 17.5 M 11 M 10.7 M 16 M 17.1 M 18.5 M 13.4 M 13.4 M 10.2 M 12.6 M 8.84 M 10.1 M 10.2 M 9.52 M 5.57 M 4.22 M - 2.99 M 3.37 M 3.08 M - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Nabriva Therapeutics plc (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Repare Therapeutics Repare Therapeutics
RPTX
- - $ 112 M canadaCanada
Sesen Bio Sesen Bio
SESN
- 7.29 % $ 127 M usaUSA
Windtree Therapeutics Windtree Therapeutics
WINT
- - $ 26.8 M usaUSA
Trean Insurance Group Trean Insurance Group
TIG
- - $ 316 M usaUSA
SQZ Biotechnologies Company SQZ Biotechnologies Company
SQZ
- 57.95 % $ 12.8 M usaUSA
MEI Pharma MEI Pharma
MEIP
- 10.43 % $ 20.5 M usaUSA
Palatin Technologies Palatin Technologies
PTN
- - $ 13 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
ММЦБ ММЦБ
GEMA
- - - russiaRussia
Lyra Therapeutics Lyra Therapeutics
LYRA
- - $ 24.9 M usaUSA
ОЗОН Фармацевтика ОЗОН Фармацевтика
OZPH
- - - russiaRussia
Промомед Промомед
PRMD
- - - russiaRussia
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
ESSA Pharma ESSA Pharma
EPIX
- - $ 8.86 M canadaCanada
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
- - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
- - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
- - $ 2.36 B usaUSA
Annexon Annexon
ANNX
$ 3.11 -8.94 % $ 482 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Galapagos NV Galapagos NV
GLPG
- - $ 1.83 B belgiumBelgium
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
$ 4.63 21.05 % $ 20 M israelIsrael
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 6.78 0.89 % $ 296 M usaUSA
Leap Therapeutics Leap Therapeutics
LPTX
- 368.57 % $ 41.9 M usaUSA
Lumos Pharma Lumos Pharma
LUMO
- - $ 35.3 M usaUSA
Gamida Cell Ltd. Gamida Cell Ltd.
GMDA
- -18.25 % $ 5.04 M israelIsrael
Axcella Health Axcella Health
AXLA
- -16.42 % $ 249 M usaUSA
Metacrine Metacrine
MTCR
- - $ 24.2 M usaUSA
Zealand Pharma A/S Zealand Pharma A/S
ZEAL
- 0.52 % $ 821 M danmarkDanmark
Myovant Sciences Ltd. Myovant Sciences Ltd.
MYOV
- -0.04 % $ 2.62 B usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
Idera Pharmaceuticals Idera Pharmaceuticals
IDRA
- -23.04 % $ 26.6 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Verona Pharma plc Verona Pharma plc
VRNA
- - $ 69.7 B britainBritain
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
Guardion Health Sciences Guardion Health Sciences
GHSI
- -0.31 % $ 3.64 M usaUSA
Opiant Pharmaceuticals Opiant Pharmaceuticals
OPNT
- - $ 109 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
ImmunoGen ImmunoGen
IMGN
- - $ 7.92 B usaUSA
Vascular Biogenics Ltd. Vascular Biogenics Ltd.
VBLT
- -8.77 % $ 12.4 M israelIsrael
Cidara Therapeutics Cidara Therapeutics
CDTX
- - $ 1.41 B usaUSA
Iterum Therapeutics Iterum Therapeutics
ITRM
- - $ 591 K irlandaIrlanda
Virpax Pharmaceuticals Virpax Pharmaceuticals
VRPX
- -45.12 % $ 2.85 M usaUSA
Navidea Biopharmaceuticals Navidea Biopharmaceuticals
NAVB
- -2.99 % $ 2.47 M usaUSA
Stealth BioTherapeutics Corp Stealth BioTherapeutics Corp
MITO
- - $ 23.9 M usaUSA
OncoSec Medical Incorporated OncoSec Medical Incorporated
ONCS
- 31.87 % $ 1.61 M usaUSA